No data to show
OTCM
PETV
Market cap19mUSD
Aug 01, Last price
0.81USD
1D
0.88%
1Q
27.89%
Jan 2017
-54.61%
IPO
467.42%
Name
PetVivo Holdings Inc
Chart & Performance
P/E
—
P/S
20.32
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.81%
Rev. gr., 5y
65.54%
Revenues
969k
+5.62%
Net income
-11m
L+25.90%
CFO
-7m
L+9.20%
Earnings
Aug 12, 2025
Profile
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | |||||||||
Revenues | 969 5.62% | 917 693.49% | |||||||
Cost of revenue | 11,590 | 9,651 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (10,621) | (8,733) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (16) | ||||||||
Tax Rate | |||||||||
NOPAT | (10,621) | (8,718) | |||||||
Net income | (10,955) 25.90% | (8,702) 76.09% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 6,527 | 1,527 | |||||||
BB yield | -43.67% | -5.43% | |||||||
| Debt | |||||||||
Debt current | 348 | 85 | |||||||
Long-term debt | 1,221 | 578 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 1,481 | 188 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (7,420) | (6,794) | |||||||
CAPEX | (424) | ||||||||
Cash from investing activities | (309) | (424) | |||||||
Cash from financing activities | 7,341 | 1,587 | |||||||
FCF | (11,592) | (9,130) | |||||||
| Balance | |||||||||
Cash | 87 | 475 | |||||||
Long term investments | |||||||||
Excess cash | 39 | 429 | |||||||
Stockholders' equity | (82,782) | (71,696) | |||||||
Invested Capital | 84,833 | 72,773 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 13,970 | 10,223 | |||||||
Price | 1.07 -61.09% | 2.75 34.80% | |||||||
Market cap | 14,948 -46.83% | 28,113 57.30% | |||||||
EV | 16,429 | 28,301 | |||||||
EBITDA | (10,494) | (8,619) | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||